Venaxis Inc

Find Ratings Reports
APPY : NASDAQ : Health Care
$3.95 -0.28 | -6.62%
Today's Range: 3.8 - 4.15
Avg. Daily Volume: 85900.0
12/08/16 - 4:00 PM ET

Financial Analysis


VENAXIS INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. VENAXIS INC is extremely liquid. Currently, the Quick Ratio is 12.64 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has decreased by 9.89% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)0.030.08
EBITDA ($mil)-1.63-1.56
EBIT ($mil)-1.64-1.59
Net Income ($mil)-1.71-1.58


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)14.8618.93
Total Assets ($mil)19.3223.08
Total Debt ($mil)0.222.26
Equity ($mil)17.0318.9


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin-6048.15-1919.75
EBITDA Margin-6048.14-1919.75
Operating Margin-6066.67-1964.2
Sales Turnover0.010.01
Return on Assets-25.57-35.4
Return on Equity-29.01-43.24
Debt Q3 FY16 Q3 FY15
Current Ratio13.2617.36
Debt/Capital0.010.11
Interest Expense0.00.03
Interest Coverage-546.0-61.19


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)4.53.87
Div / share0.00.0
EPS-0.43-0.4
Book value / share3.784.88
Institutional Own % n/a n/a
Avg Daily Volume84169.031920.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.12 indicates a significant discount versus the S&P 500 average of 2.82 and a significant discount versus the industry average of 11.06. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, VENAXIS INC seems to be trading at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
APPY NM Peers 33.44   APPY NM Peers 25.93

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

APPY's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

APPY's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
APPY NA Peers 23.71   APPY NA Peers 0.41

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
APPY 1.12 Peers 11.06   APPY 43.06 Peers 3.13

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

APPY is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

APPY is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
APPY 173.61 Peers 151.50   APPY -59.71 Peers 514.21

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

APPY is trading at a premium to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

APPY significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades